Wall Street closes higher, boosted by healthcare as investors shrug off jobs data, US shutdown

U.S. stock indexes closed higher on Wednesday, with the S&P 500, Dow, and Nasdaq advancing despite weaker-than-expected private payroll data and the initial day of a government shutdown. The healthcare sector led gains, primarily driven by pharmaceutical companies after Pfizer struck a deal with President Trump to lower Medicaid drug prices in exchange for tariff relief, signaling potential industry-wide implications. Investors largely overlooked the government shutdown uncertainty, consistent with historical market resilience during such events, while the tech sector also contributed positively and materials lagged.

Analysis

U.S. equity markets demonstrated notable resilience, with the S&P 500, Dow, and Nasdaq all closing higher despite facing headwinds from a weaker-than-expected ADP private payrolls report and the onset of a federal government shutdown. The ADP data showed an unexpected decline of 32,000 private payrolls, contrary to forecasts for a 50,000 gain. Investors, however, appeared to discount this negative economic signal, a sentiment reinforced by historical data from Deutsche Bank showing the S&P 500 has risen during the last six government shutdowns. The primary catalyst for the market's advance was the healthcare sector (.SPXHC), which rallied following a deal between Pfizer (PFE) and the U.S. administration to lower certain drug prices in exchange for tariff relief, boosting names like Biogen (BIIB) and Thermo Fisher (TMO) by 10.9% and 9.4%, respectively. The technology sector (.SPLRCT) also contributed significantly, with Micron (MU) rallying 8.9%. In contrast, the materials sector (.SPLRCM) was the session's weakest, declining over 1%. Corporate-specific events drove significant volatility; AES Corp (AES) surged 16.8% on reports of a potential $38 billion acquisition, Lithium Americas (LAC) rallied 23.3% on a government investment, while Corteva (CTVA) fell 9% after announcing plans to split into two companies. Market breadth was positive, with advancing issues outnumbering decliners, and volume was above the 20-day average, suggesting conviction behind the day's gains.

Key Decisions for Investors

• Consider the healthcare sector's renewed strength, as the Pfizer deal may signal a reduction in political risk and a potential catalyst for rotation into previously underperforming pharmaceutical and biotech stocks.
• Recognize that the market is currently prioritizing sector-specific catalysts and corporate actions over negative macroeconomic data and political uncertainty, suggesting a focus on fundamental, bottom-up stock selection.
• Monitor event-driven situations closely, as M&A speculation (AES), government investments (LAC), and corporate restructurings (CTVA) are creating significant, stock-specific price movements independent of broader market trends.
• While the materials sector is showing weakness, investors should differentiate within the group, as strategic assets like lithium producers are demonstrating strong performance due to targeted government and corporate interest.